Foghorn Therapeutics Inc Forecast, price target & analysts
Foghorn Therapeutics Inc Target price 2026 - Analyst rating & recommendation
Foghorn Therapeutics Inc Classifications & Recommendation
Foghorn Therapeutics Inc Price Target
| Target Price | $12.24 |
| Price | $3.50 |
| Potential |
249.71%
register free of charge
|
| Number of Estimates | 11 |
|
11 Analysts have issued a price target Foghorn Therapeutics Inc 2027 .
The average Foghorn Therapeutics Inc target price is $12.24.
This is
249.71%
register free of charge
$14.70
320.00%
register free of charge
$9.09
159.71%
register free of charge
|
|
| A rating was issued by 16 analysts: 15 Analysts recommend Foghorn Therapeutics Inc to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Foghorn Therapeutics Inc stock has an average upside potential 2027 of
249.71%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million $ | 30.91 | 34.60 |
| 36.77% | 11.93% | |
| EBITDA Margin | -254.87% | -221.03% |
| 40.72% | 13.28% | |
| Net Margin | -240.31% | -158.89% |
| 37.30% | 33.88% |
12 Analysts have issued a sales forecast Foghorn Therapeutics Inc 2026 . The average Foghorn Therapeutics Inc sales estimate is
This results in the following potential growth metrics:
4 Analysts have issued an Foghorn Therapeutics Inc EBITDA forecast 2026. The average Foghorn Therapeutics Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
13 Foghorn Therapeutics Inc Analysts have issued a net profit forecast 2026. The average Foghorn Therapeutics Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -1.18 | -0.94 |
| 25.32% | 20.34% | |
| P/E | negative | |
| EV/Sales | 1.16 |
13 Analysts have issued a Foghorn Therapeutics Inc forecast for earnings per share. The average Foghorn Therapeutics Inc EPS is
This results in the following potential growth metrics and future valuations:
Foghorn Therapeutics Inc...
Current Foghorn Therapeutics Inc Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Wedbush |
Locked
➜
Locked
|
Locked | Mar 12 2026 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Mar 10 2026 |
| Jefferies |
Locked
➜
Locked
|
Locked | Feb 17 2026 |
| BTIG |
Locked
➜
Locked
|
Locked | Dec 18 2025 |
| Stifel |
Locked
➜
Locked
|
Locked | Dec 04 2025 |
| Guggenheim |
Locked
➜
Locked
|
Locked | Nov 07 2025 |
| JMP Securities |
Locked
➜
Locked
|
Locked | May 15 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Wedbush:
Locked
➜
Locked
|
Mar 12 2026 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Mar 10 2026 |
|
Locked
Jefferies:
Locked
➜
Locked
|
Feb 17 2026 |
|
Locked
BTIG:
Locked
➜
Locked
|
Dec 18 2025 |
|
Locked
Stifel:
Locked
➜
Locked
|
Dec 04 2025 |
|
Locked
Guggenheim:
Locked
➜
Locked
|
Nov 07 2025 |
|
Locked
JMP Securities:
Locked
➜
Locked
|
May 15 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
